At the 2019 Congress of the European Society of Medical Oncology, PARP inhibitors continued their victory march. With the success of the PAOLA-1 trial, reported in Friday's plenary session, as well as the PRIMA and VELIA/GOG-3005 trials, "we've got new front-line data that really introduces a paradigm shift into the way we're going to treat ovarian cancer in the coming years," Jonathan Ledermann, professor of medical oncology at University College London, told the audience at a session on new options on ovarian cancer.
BARCELONA, Spain – Sunday's Presidential Symposium at the 2019 Congress of the European Society of Medical Oncology was devoted to breast cancer studies, and two of those studies – MONARCH-2 and MONALEESA-3 – reported an overall survival (OS) benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive (HR+) breast cancer in several different settings.
BARCELONA, Spain – At the 2019 Conference of the European Society of Medical Oncology (ESMO), results from the ClarIDHy and FIGHT-202 trials, both testing drugs for the treatment of cholangiocarcinoma, illustrated how molecular medicine can bring new treatments to rare tumors.
The leucine-repeat rich kinase 2 (Lrrk2) gets most of its attention in the context of Parkinson's disease (PD). Variants in Lrrk2 are a major cause of familial PD (though familial PD makes up only a small fraction of overall PD cases).
CAR T cells engineered to target fibroblast activating protein (FAP) could reverse cardiac fibrosis and restore cardiac function in mice, researchers have reported in the Sept. 12, 2019, issue of Nature.